CytomX shifts towards EpCAM
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
